Recombinant Human ACE2 (APN01) as a Treatment for Patients With COVID-19
COVID-19
Enrolment: 185 · Results not recorded
Loading the evidence…
Biologic · Recombinant human ACE2 enzyme (angiotensin II-degrading carboxypeptidase; SARS-CoV-2 decoy receptor); no discrete ChEMBL MoA record
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
COVID-19
Enrolment: 185 · Results not recorded
COVID-19
Enrolment: 40 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: bleomycin-induced acute lung injury and fibrosis, bleomycin 1.5 U/kg in 50 microlitres intratracheally, controls receiving 50 microlitres sterile 0.9% saline
rhACE2 improved survival, exercise capacity and lung function and reduced collagen deposition and profibrotic and inflammatory mediators after bleomycin, whereas ACE2 deletion worsened fibrosis, more so in males than females.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.